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Objective methods for quantifying patients’ movement capacity would be useful in evaluat-
ing progression and interventions in neurodegenerative diseases. The Posturo-Locomotor-
Manual (PLM) test is a standardized automated movement test developed to measure
hypokinetic movements in patients with Parkinsonism. Our hypotheses were that the PLM
movement time (MT) correlates with the Unified Parkinson’s disease rating scale (UPDRS
III) motor section, and that the components of the PLM test correlate with the corre-
sponding constructed domains of UPDRS III. We also evaluated the coherence between
the results of the two assessment methods after a test dose of levodopa (L-DOPA). We
assessed motor function using the PLM method and UPDRS III in parallel, in the absence
of medication and after administration of 200 mg L-DOPA, in 73 patients with moderate to
advanced Parkinsonism: 47 with Parkinson’s disease (PD), 17 with multiple system atro-
phy (MSA), and 9 with progressive supranuclear palsy (PSP). There was a fair correlation
between the two assessment tools in the PD patients but not in the MSA or PSP patients.
In the full dataset, there was a fair to good correlation between UPDRS III and the PLM
MT. At group level, the UPDRS III L-DOPA test differentiated PD from MSA/PSP, whereas
the PLM L-DOPA test differentiated between all three diagnoses.
Keywords: Parkinson’s disease, Parkinsonism, movement disorders, L-DOPA test, optoelectronic movement
analysis, PLM test, UPDRS III
INTRODUCTION
The clinical diagnosis of Parkinson’s disease (PD) requires
bradykinesia and at least one of resting tremor, rigidity, or loss
of postural reflexes (1, 2). A number of different scales have been
used to grade the extent of motor and non-motor symptoms and
progression of PD (3). The unified Parkinson’s disease rating scale
(UPDRS) is currently the most widely used and evaluated scale,
and is the gold standard in clinical PD research (4, 5). It is used
internationally as a clinical tool to asses Parkinsonism (6), as a
marker for disease progression (7), and to evaluate the outcome
of interventions (8).
As a complement to a clinical examination, objective methods
have been proposed, such as gait quantification and timed tests
(e.g., pronation-supination test, finger dexterity, and stand-walk-
sit test) (9, 10). Appropriate symptom evaluation methods are
essential, both for monitoring disease progress and for evaluat-
ing the efficacy of a growing number of treatment interventions.
For motor symptoms, rater-independent quantitative evaluation
methods that allow repeated measurements are desirable (11).
One advantage of using objective quantitative assessment is that
it reduces the elements of bias or error that can enter into an
assessment process (12), such as inter-rater variability (depending
upon the personal skills and experience of each examiner) and
intra-rater variability (13).
Another important factor is the timing of symptom assessments
after oral drug administration. The time of medication effect onset
depends on the gastric emptying frequency, which may decrease
with the progress of PD (14–18). In addition, some patients expe-
rience a short-lived worsening of Parkinsonian symptoms for up
to 20 min after l-DOPA uptake (19). Assessing symptoms at the
right time point is therefore not a trivial task. Timing is less crucial
when using continuous or repeated symptom evaluation methods,
as these methods record the optimal effect as well as the effect
duration. Another aspect of repeated measurements is that they
provide information about symptom variability, which makes it
possible to decide if a medication-induced change in performance
is also statistically significant in individual patients.
The Posturo-Locomotor-Manual (PLM) method was designed
to quantify, in a single test, the movement aspects of postural
control, locomotion, and goal-directed hand movements and
the efficacy with which these movements integrate to a smooth
dynamic performance (20, 21). This test is automated and rater-
independent, and although it tests a limited set of movements, the
movements are chosen to reflect an everyday situation and to sam-
ple capacities in several domains including balance, locomotion,
and basic manual function. The PLM test has been used for more
than 10 years in some Swedish neurological clinics to consecu-
tively evaluate hypokinetic symptoms in PD patients and l-DOPA
responsiveness, and it is now a commercial product. However, it
has not been validated against other methods, and in particular
not against UPDRS III, which is the current gold standard for
assessing motor symptoms in PD (5, 22, 23).
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We hypothesized that the PLM method correlates with the
UPDRS III, and that the different phases (Postural, Locomotor,
and Manual) of the PLM test correlate with constructed domains
of the UPDRS III. We also hypothesized that a significant improve-
ment in the PLM test after a test dose of l-DOPA predicts an
improvement in UPDRS III scores.
MATERIALS AND METHODS
PATIENTS
We retrospectively studied clinical rating and PLM measurements
in 73 patients with Parkinsonism who were referred to the move-
ment laboratory to perform an l-DOPA test: 47 with PD, 17
with multiple system atrophy (MSA), and 9 with progressive
supranuclear palsy (PSP). Patients’ characteristics are presented
in Table 1.
Motor function was evaluated by the PLM method and UPDRS
III in OFF and ON states to determine if the patient responded pos-
itively to a test dose of l-DOPA. The patients had given informed
consent to the testing procedure before the assessments, and ret-
rospective analysis of the anonymized collected data was approved
by the Regional Ethical Review Board in Gothenburg, Sweden.
The PLM results for three PD patients with freezing of gait
phenomena that yielded very long movement times (MTs) in OFF
were omitted from the correlation analysis, as they were clear
outliers in the PLM test and might have skewed this analysis.
For seven patients, only the total UPDRS III scores were doc-
umented in the medical records; the subscores for the different
items were not available. Those seven individuals were all PD
patients, and were excluded from the correlation analyses between
PLM and the different UPDRS III domains (data presented in
Table 3).
THE PLMMETHOD
The PLM method is designed to assess movement patterns in
patients with hypokinetic syndromes. The test movement is a
compound movement involving a postural phase P (rising up),
a locomotion phase L (walking), and a manual phase M (pendu-
lous arm movement and positioning of a test object on a pedestal,
Figure 1). An infrared camera system is used to register body
movements by tracking the position of six reflective ball markers
of 4 cm diameter. The markers are attached to the patient’s head;
to the shoulder, arm, hip, and calf of the most severely disabled
side of the body; and to the contralateral foot. A seventh marker
is located on a test object consisting of a 500 g metal handle on a
cylindrical horizontal plate (24–26). An automated tracking algo-
rithm is used to identify the markers and analyze the recorded data.
The total MT is calculated along with the duration of the different
movement phases P, L, and M (27), and the software produces a
report after a full test session.
At the start of the test, the patient is asked to stand erect with
feet together at a clearly marked start position with the test object
on the floor beside them. When instructed, the participant lifts
the object from the floor, walks forward as quickly as possible, and
places the object on a stand located 1.5 m away at chin height.
This movement is performed three times, after which the patient
rests for a short while. Three consecutive movements constitute
a measurement group. Ten measurement groups are collected to
allow the patient to reach a performance plateau. Mean MT, P, L,
and M durations are automatically calculated from the three best
consecutive groups. All nine individual measurements from these
three groups are used to calculate standard deviations for each
variable.
TEST PROCEDURE
The PLM test and the UPDRS rating were carried out in the same
clinical movement laboratory. All antiparkinsonian medication
was withheld for at least 12 h prior to performing the l-DOPA test,
as recommended in published guidelines (10). A trained move-
ment disorder physiotherapist administered the motor part of the
UPDRS as described by Goetz et al. (6) before the PLM test started
(UPDRS III OFF), and 69 min (±32 min) after administration of
200 mg of l-DOPA (UPDRS III ON).
A trained biomedical analyst instructed all patients and per-
formed the PLM test. First, 10 baseline groups of PLM measure-
ments were performed, and the three fastest consecutive groups
were designated best mean “OFF” performance. Next, the patients
were given 200 mg of l-DOPA (Madopar®, 200 mg) dispersed in
water (28) and allowed to rest for 31 min (±20 min). Following
this, two consecutive groups of PLM measurements were collected
every 10 min for 2 h (Figure 2) to ensure that measurements were
obtained at the time of maximum l-DOPA effect (18). The three
fastest consecutive groups of measurement after l-DOPA admin-
istration were designated best mean “ON” performance; these
occurred 63± 25 min after drug administration.
Table 1 | Patient characteristics.
Diagnosis PD (n=47) MSA (n=17) PSP (n=9)
Age (mean±SD, range) 61.9±7.2 (52–76) 53.9±9.0 (43–68) 64.7±10.4 (44–75)
Males/females 29/18 12/5 7/2
Hoehn and Yahr ON (median, range) 2.5, 1–3
UPDRS OFF (mean±SEM, range) 35.7±1.7, 6–59 31.6±3.1, 15–61 32.7±2.6, 17–46
UPDRS ON (mean±SEM, range) 19.1±1.7, 2–61 29.7±3.1, 13–60 29.8±7.0, 18–44
MT OFF (mean±SEM, range) 3.5±0.4, 1.6–19.3 3.8±0.6, 1.8–10.6 8.6±3.9, 2.6–38.7
MT ON (mean±SEM, range) 2.1±0.1, 1.2–4.5 3.6±0.5, 1.7–8.7 7.9±3.25, 1.8–30.8
Disease duration (mean±SD) 13.1±5.7 3.4±2.1 4.0±3.6
Treatment (mg LDE, mean±SD) 1258±605 492±525 494±578
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FIGURE 2 |Timeline for the L-DOPA test.
UPDRS III DOMAINS AND PLM VARIABLES
The MT variable of the PLM method was compared to the total
score of the UPDRS III (UPDRS items 18–31) as well as to a ver-
sion of the UPDRS III where scores for speech, facial expression,
resting tremor, and postural tremor had been excluded UPDRS
(−). We also analyzed the correlations between the different PLM
phases and a number of corresponding constructed domains of
the UPDRS III (Table 2). The UPDRS III items reflecting postural
instability and gait difficulties (PIGD, items 27–30) were evaluated
separately against the PLM variables MT, P, and L.
POSITIVE L-DOPA RESPONSE
Patients who improved by six points or more in UPDRS III score
after a test dose of 200 mg l-DOPA were considered to have a
positive l-DOPA response (29). We also report the results and con-
cordance between the two tests with some alternative cut off values
for acute l-DOPA response: improvements in UPDRS III of 10
points or more, 30, and 50%. A change in MT was considered pos-
itive if the confidence interval for MT OFF (MT OFF± 1.96 SD)
Table 2 | UPDRS III domains and PLM variables.
PIGD* (postural domain+gait) Item 27 Arising from a chair
Item 28 Posture
Item 29 Gait
Item 30 Postural stability
Postural domain Item 27 Arising from a chair
Item 28 Posture
Item 30 Postural stability
Rigidity Item 22 Neck
Leg domain Item 26 Leg agility
Item 29 Gait
Rigidity Item 22 Leg
Hand/arm domain** Item 23 Finger taps
Item 24 Opening and closing the fist
Item 25 Pronation and supination
Rigidity** Item 22 Arm
*Postural instability and gait difficulty score.
**Most affected side.
was numerically higher and disjoint from the confidence interval
for MT ON (MT ON± 1.96 SD).
STATISTICAL METHODS
Mean, SD, SEM, median, and range of data were used for descrip-
tive purposes. All correlation analysis was performed using Spear-
man’s non-parametric correlation coefficient. All p-values were
two-tailed and conducted at the 5% significance level. The follow-
ing criteria were used to evaluate the strength of the correlations:
fair (0.25–0.49), good (0.50–0.74), and excellent (0.75 and above)
(30). Agreements between UPDRS III and PLM MT l-DOPA tests
were tested with McNemar’s test after categorizing the response as
positive or negative. Analysis of UPDRS III and PLM results at the
level of diagnostic groups was done with two-way ANOVA, with
diagnosis and treatment state as independent factors and UPDRS
III or PLM as the dependent variables. Post hoc comparisons were
made with Bonferroni corrected t -tests.
RESULTS
UNIFIED PARKINSON’S DISEASE RATING SCALE III
The baseline OFF UPDRS III scores and the assessments after a
test dose of l-DOPA are given in Table 1.
The effect of l-DOPA treatment was evaluated by repeated
measure two-way ANOVA with diagnosis and treatment state
as independent variables and UPDRS III as the dependent vari-
able. There was a significant interaction between diagnosis and
treatment state: F(2,70)= 17.5, p< 0.0001, and a significant main
effect of treatment state: F(1,70)= 24.2, p< 0.001. The interac-
tion was explained by a reduction in ON UPDRS III scores in PD
patients (Figure 3A).
POSTURO-LOCOMOTOR-MANUAL
The baseline OFF PLM results and the results after a test dose of
l-DOPA are given in Table 1.
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FIGURE 3 | (A) UPDRS III scores before (OFF) and after (ON) 200 mg
L-DOPA, stratified over the three diagnoses: Parkinson’s disease (PD),
multiple system atrophy (MSA), and progressive supranuclear palsy (PSP).
(B) PLM mean movement time, MT(s), duration. Main effects of diagnosis
and treatment state were analyzed with repeated measure two-way
ANOVA followed by Bonferroni corrected t -tests where ***p<0.001, PD
OFF vs. PD ON, *p<0.05, **p<0.01.
The effect of l-DOPA treatment was evaluated by repeated
measure two-way ANOVA using diagnosis and treatment state
as independent factors. There was a significant main effect
of treatment state: F(1,70)= 5.2, p= 0.0258, and of diagnosis:
F(2,70)= 7.1, p= 0.0016. Post hoc analysis revealed that PSP
patients had longer MT than the other patient groups in both
ON and OFF, and that MT decreased in PD patients but not in
MSA or PSP patients after l-DOPA (Figure 3B).
CORRELATIONS BETWEEN UPDRS III AND THE PLM TEST
In the full dataset, fair to good correlations were found between
most UPDRS III domains and the corresponding PLM phases.
There was also significant correlation between the l-DOPA
induced effects observed with UPDRS III and PLM (Table 3).
Overall, the correlations were lower in OFF than in ON and
OFF-ON (magnitude of change after l-DOPA administration).
No or low correlations were found between the L phase and
leg rigidity and between the M phase and the corresponding
constructed UPDRS III domains. Fair and significant correla-
tions between UPDRS III and PLM MT were found with PD
patients in OFF, ON, and OFF-ON, but not consistently for MSA
and PSP patients, with the exception of OFF-ON in the small
sample of PSP patients, where there was excellent correlation
(Table 4).
L-DOPA RESPONSE AT SUBJECT LEVEL
The majority of PD patients responded positively to a test dose
of l-DOPA as measured with either method. A decrease of six
or more points in UPDRS III classified 40/47 of the PD patients
as responders, compared to 34/47 with the PLM method; the
concordance between the two test methods was 70%. Few of
the MSA patients showed improvement after medication with
either method (UPDRS 4/17, PLM 3/17); here, the concordance
between the two methods was 59%. In the small sample of PSP
patients, about 20% responded positively to l-DOPA (UPDRS
2/9, PLM 2/9), with a concordance of 78% between the methods
(Table 5).
The Parkinson’s disease patients who were discordantly l-
DOPA negative in the PLM test displayed significantly larger
variability in PLM performance before and after l-DOPA adminis-
tration. The PLM MT standard deviation in this group was 339%
of the l-DOPA induced change in performance, whereas it was
70% in the group that was l-DOPA responsive with both meth-
ods, and 29% in the group that was positive in the PLM test
only [one-way ANOVA of logarithmized values: F(2,51)= 12.5,
p< 0.0001]. A post hoc t -test revealed significant differences
between PLM negative/UPDRS positive patients and the other
two groups (p< 0.0001 in both cases).
DISCUSSION
This study was designed to validate the objective and quantita-
tive PLM method for assessing Parkinsonism, by comparing this
method with the commonly used clinical rating scale UPDRS part
III. There was a fair correlation between the PLM (MT) and the
UPDRS assessment in PD but not in MSA and PSP patients. Over-
all, the correlations were somewhat stronger in ON and OFF-ON
than in OFF. The postural and locomotive phases of the compound
PLM movement showed good correlation to the pre-constructed
corresponding domains in the UPDRS when evaluated in the full
dataset. However, the movement phase of the PLM test did not
correlate with the hand and arm related domains of the UPDRS.
The degree of correlation between the two evaluation methods
may appear modest in places, but since our purpose was to exam-
ine the relationship between a subjective clinical rating scale and a
quantitative analysis of motor function, establishing a fair corre-
lation is a clinically useful validation of the quantitative method.
As the PLM method is more expensive than clinical rating, and is
also time consuming if the medication response profile is followed
beyond maximum effect, a very high correlation would have sug-
gested that the PLM test adds no information beyond that obtained
from the UPDRS.
There are several differences between the UPDRS III and the
PLM test. In particular, the UPDRS III measures some motor fea-
tures that go undetected in the PLM test, such as tremor, speech,
and facial expression. The PLM test also contains no alternating
movements, which may explain the lack of correlation between
the arm/hand domain of the UPDRS III and the M phase in the
PLM test. We hypothesized that the pendulous arm movement
of the M phase might correspond better to arm rigidity than to
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Table 3 | Correlation between PLM results and the UPDRS in all patients.
OFF ON OFF-ON
r p-Value n r p-Value n r p-Value n
MT vs. UPDRS (total) 0.37 0.0017 70* 0.58 <0.0001 73 0.60 <0.0001 70*
MT vs. UPDRS (−) 0.35 0.0042 64** 0.56 <0.0001 66** 0.58 <0.0001 64**
MT vs. bradykinesia 0.39 0.0013 64 0.62 <0.0001 66
MT vs. PIGD 0.56 <0.0001 64 0.62 <0.0001 66
P phase vs. postural domain 0.36 0.0030 64 0.65 <0.0001 66
P phase vs. neck rigidity 0.22 0.0806 64 0.41 0.0006 66
P phase vs. PIGD 0.48 <0.0001 64 0.70 <0.0001 66
L phase vs. leg domain 0.51 <0.0001 64 0.64 <0.0001 66
L phase vs. leg rigidity −0.16 0.2186 64 0.04 0.7474 66
L phase vs. PIGD 0.55 <0.0001 64 0.53 <0.0001 66
M phase vs. hand/arm domain*** 0.09 0.4925 64 0.29 0.0172 66
M phase vs. arm rigidity*** −0.07 0.5828 64 0.12 0.3310 66
UPDRS (−) excluding scores for speech, facial expression, resting tremor, and postural tremor.
PIGD postural instability gait difficulty score (UPDRS Items 27–30).
*The PLM results for three PD patients in OFF were omitted from the correlation analysis due to freezing of gait phenomena yielding very long movement times.
**UPDRS III subscores were not available for all patients.
***Most affected side.
Table 4 | Correlation between PLM MT(s) and UPDRS III for each
diagnosis.
OFF ON OFF-ON
r p-Value n r p-Value n r p-Value n
PD 0.47 0.0013 44* 0.44 0.0019 47 0.47 0.0015 44*
MSA 0.49 0.0448 17 0.46 0.0635 17 0.05 0.8544 17
PSP 0.27 0.4860 9 0.22 0.5755 9 0.75 0.0210 9
*The PLM results for three PD patients in OFF were omitted from the correlation
analysis due to freezing of gait phenomena yielding very long movement times.
hand bradykinesia, but this assumption was not supported by the
correlation analysis.
The presence of tremor strongly influences the UPDRS III
scores, but has no practical effect in PLM. Nevertheless, remov-
ing tremor and facial features from UPDRS III did not improve
the correlation between UPDRS III and PLM MT. This suggests
that the tremor rating does not contribute fundamentally dif-
ferent information from that captured by PLM. Consequently,
it appears that the PLM test gives a fair to good estimate of
overall Parkinson symptomatology, but it is clear that the PLM
test covers fewer domains of Parkinsonism and its face valid-
ity is therefore lower than that of UPDRS (7). The advantage of
the PLM test is the rater-independent outcome and the repeated
measurements that eliminate inter-rater variability and provide a
measure of the patient’s performance and symptom variability.
As a consequence, it is possible to determine whether a treat-
ment has a significant effect in a single patient. It is also our
experience that, in some cases, being able to present objective
improvements over time has a pedagogical value and may improve
compliance.
We registered significant improvements in PD patients follow-
ing acute l-DOPA treatment with both the UPDRS III and the
PLM method, but no such improvements were seen in the MSA
or PSP group. Interestingly, the PLM test and the UPDRS III pro-
vided different information on a group level, as PSP patients had
significantly higher MT than the other diagnostic groups but were
not singled out by their UPDRS III scores. However, the PSP group
was small, and the significantly higher MT needs to be confirmed
in a larger population with atypical Parkinsonism.
Different cut off values for UPDRS improvements have been
used to categorize subjects as l-DOPA responsive or not. Schrag
et al. (29) suggested that a decrease of more than five points
in UPDRS III after l-DOPA administration represents a mini-
mal clinically relevant improvement in motor ability. Others have
defined responders as those improving by 30% in UPDRS III score
(31); however, the outcome then largely depends on baseline score,
so more advanced patients have lesser probability of demonstrat-
ing a positive effect. Because a clinically relevant improvement is
the most appropriate reason for introducing or continuing treat-
ment, we argue that a six-point cut off is preferable. This is further
corroborated by our finding that the 6-point cut off identified
more l-DOPA responders than a 10-point, 30, or 50% improve-
ment in UPDRS III, and had the best overlap with the PLM method
(Table 5).
Because the PLM test covers a smaller subset of l-DOPA
responsive features, the somewhat lower ratio of l-DOPA respon-
ders revealed by the PLM method in our material was as expected.
However, it was also evident that the group of patients who were
l-DOPA-responsive with UPDRS III, but not PLM, displayed sig-
nificantly larger variability in PLM MT both in OFF and ON,
whereas patients who were positive only with the PLM test had a
significantly lower variability in MTON. Patients who were con-
gruent in both tests showed low variability both in OFF and ON.
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Table 5 | L-DOPA responses with the two measuring tools.
UPDRS improvement cut off PD (n=47) MSA (n=17) PSP n(9)
≥6 p ≥10 p ≥30% ≥50% ≥6 p ≥10 p ≥30% ≥50% ≥6 p ≥10 p ≥30% ≥50%
Positive in PLM 34 34 34 34 3 3 3 3 2 2 2 2
Negative in PLM 13 13 13 13 14 14 14 14 7 7 7 7
Positive in UPDRS 40 35 34 28 4 0 1 0 2 0 0 0
Negative in UPDRS 7 12 13 19 13 17 16 17 7 9 9 9
Concordant positive in PLM (%) 64 57 55 47 0 0 0 0 11 0 0 0
Concordant negative in PLM (%) 6 11 11 15 59 82 76 82 67 78 78 78
Discordant (%) 30 32 34 38 41 18 24 18 22 22 22 22
This was an unexpected but interesting finding, indicating that
the PLM method has the ability to detect variability in motor per-
formances both OFF and ON medication, and that the variability
differs between patients; some patients have a large variability in
OFF, others have a large variability in both OFF and ON, and
yet others have a very small variability after administration of l-
DOPA as compared to before administration of l-DOPA. This
may to some extent explain why the PLM test is less sensitive than
UPDRS III in detecting l-DOPA improvement, because for a pos-
itive l-DOPA response in the PLM test the improvement has to
be statistically significant, but with UPDRS it only has to be more
than five points.
This raises the question of the best timing of the assessment
after an l-DOPA dose. The repeated measurements obtained with
the PLM method reveal highly variable performances in some
patients. The variability in performance will not be detected if a
single UPDRS rating is performed before and at a defined time
point after treatment (15, 18, 32, 33). This may be an advantage
of the PLM test, but the clinical relevance of detecting motor
performance variability is to our knowledge not known. The
repeated PLM tests indicated that optimal improvement after l-
DOPA occurred 63± 25 min after administration, so a 1-h wait
after administering l-DOPA dispersed in water before evaluation
of effect appears appropriate. All UPDRS III ratings ON med-
ication in the present study were performed within the optimal
time span.
One obvious problem with the PLM test is that patients who
cannot walk cannot perform the test. Also, patients who experi-
ence freezing of gait phenomena may produce disproportionately
long MTs. Although this does not preclude assessment of l-DOPA
response in patients who can walk after the test dose, it introduces
a non-linear component to the PLM test. In the present dataset,
we excluded 3 out of 73 patients due to obvious freezing of gait in
OFF. Most of these patients could still be assessed in ON, and the
exclusion was made only because they were outliers in the corre-
lation analysis. Despite this general limitation, the PLM test may
still be useful for evaluating whether freezing of gait is l-DOPA
responsive in individual patients.
The current study population had relatively long mean disease
duration, and had passed the early stages when correct diagnosis
is more difficult. A prospective study of patients who have recently
presented with their first signs of hypokinetic movement disorders
would be needed to determine whether the PLM test can provide
any additional diagnostic information that might aid the clinician.
CONCLUSION
We found a fair correlation between the PLM test and a simulta-
neous UPDRS III rating in PD patients OFF and ON medication,
despite the fact that the PLM test only samples some of the dis-
abilities rated with the UPDRS III. On a group level, the PLM
method distinguished between PD, MSA, and PSP patients. The
PD patients could be identified by a positive response to l-DOPA,
and the PSP group was significantly slower than both MSA and PD
patients. The PLM method provides a measure of motor perfor-
mance variability ON and OFF medication that cannot easily be
obtained with UPDRS III. Our findings suggest that the PLM test
is a valid method for assessing motor performance in OFF and ON
state, as well as l-DOPA responsiveness in patients with Parkinson-
ism at moderately advanced stages. It remains to be seen whether
the PLM test can also reliably detect positive l-DOPA responses
in de novo PD patients less marked by their disease.
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